|
| |
List of Keynote
Speakers & Lectures
(as of July, 1999)
ETHICAL ASPECTS OF OCULAR PHARMACOLOGICAL CLINICAL STUDIES
S. Merin, Israel
THE BENEFITS AND THE DIFFICULTIES OF ACADEMIA INDUSTRY COLLABORATION - THE
INDUSTRY POINT OF VIEW
G. Cagle, USA
THE BENEFITS AND THE DIFFICULTIES OF ACADEMIA INDUSTRY COLLABORATION - THE
ACADEMIC POINT OF VIEW
C.S. Foster, USA
ACADEMIA INDUSTRY COLLABORATION - THE CONTRACT PROCESS: ACHIEVING THE RIGHT
BALANCE
A. Latham, UK
INTRAOCULAR DEVICES - MOVING FROM RESEARCH TO COMMON PRACTICE
P. Ashton, USA
METHODOLOGIES OF MEASURING DRUG DELIVERY - RELEVANCE TO DRUG DEVELOPMENT
R. Gurny, Switzerland
NON-AQUEOUS DRUG DELIVERY PLATFORMS
O. Olejnik, USA
GENE THERAPY IN IMMUNE MEDIATED DISEASES: DRUG DELIVERY DEVICES
U. Pleyer, Germany
THE EMERGENCE OF GENETIC THERAPY IN OPHTHALMOLOGY
A. Reaves, USA
TARGETS FOR FUTURE DRUG DEVELOPMENT IN GLAUCOMA
P. Kaufman, USA
THE EMERGENCE OF NEW THERAPEUTIC ALGORITHMS FOR GLAUCOMA - ARE WE BETTER
EQUIPPED TO PROTECT THE OPTIC NERVE FROM GLAUCOMATOUS DAMAGE
S. Melamed, Israel
THE USE OF CONTROLLED WOUND HEALING IN GLAUCOMA SURGERY
D.A. Lee, USA
THE LAST 20 YEARS OF DRUG DEVELOPMENT FOR GLAUCOMA - HAVE WE REALLY PROGRESSED?
T.J. Zimmerman, USA
GLAUCOMA CLINICAL STUDIES IN JAPAN
M. Araie, Japan
PEARLS AND PITFALLS OF CLINICAL STUDIES OF GLAUCOMA DRUGS
L. Metzner-Serra, Portugal
NEUROPROTECTANTS FOR THE TREATMENT OF NORMAL-TENSION GLAUCOMA
Y. Kitazawa, Japan
NEUROREPAIR: MAINTAINING FUNCTION AFTER NEUROPROTECTION
L. Levin, USA
PECULIARITIES OF OCULAR BLOOD FLOW - COMPARTMENTS AND POTENTIAL THERAPEUTIC
INTERVENTIONS
A. Harris, USA
THE ROLE OF IMAGING TECHNIQUES IN EVALUATING OCULAR PHYSIOLOGY AND DRUG EFFECTS
S. Krupsky, Israel
UNDERSTANDING INTRAOCULAR BLOOD VESSELS GROWTH - THE TRANSFER FROM ANIMAL MODELS
TO THE CLINICAL REALITY
R. D'Amato, USA
NEW PERSPECTIVES IN MEDICAL THERAPY OF DIABETIC RETINOPATHY (I)
J. Cunha-Vaz, Portugal
MEDICAL THERAPY IN DIABETIC RETINOPATHY (II)
A. Kampik, Germany
IS AMD A VASCULAR DISORDER?
E. Friedman, USA
THE ROLE OF PHOTODYNAMIC THERAPY IN OPHTHALMOLOGY: PRESENT STATUS AND FUTURE
PROSPECTS
J.W. Miller, USA
MEDICAL TREATMENT OF PROLIFERATIVE VITREORETINOPATHY (PVR)
J.C. Pastor-Jimeno, Spain
LIGANDS FOR NUCLEAR RECEPTORS INHIBIT RPE PROLIFERATION
C-L. Schoenfeld, Germany
FUTURE AND PRESENT ROLE OF CYTOKINES FOR INFLAMMATORY EYE DISEASES
M. Jager, The Netherlands
THE USE OF ANTI-SENSE TECHNOLOGY IN INFLAMMATORY EYE DISEASES
M. De Smet, The Netherlands
ORAL INDUCED IMMUNE MODULATION
S. Thurau, Germany
COMBINING ALTERNATIVE MEDICINE IN THE EFFORT TO PRESERVE VISION IN DESTRUCTIVE
INFLAMMATORY EYE DISEASES
C.Stephen Foster, USA
THE PHARMACOLOGIC ASPECT OF REFRACTIVE SURGERY
H. Wu, USA
THE ROLE OF ANTI-INFLAMMATORY DRUGS IN THE THERAPEUTIC REGIMEN OF DRY EYES
M. Calonge, Spain
NEW TRENDS ON TOPICAL ANAESTHETICS IN OPHTHALMIC SURGERY
A. Castanheira Dinis, Portugal
TOXOKINETICS OF OPHTHALMIC DRUG INTERACTIONS
J. Bartlett, USA
FRONTIERS OF ANTIMICROBIAL THERAPY IN OPHTHALMOLOGY
T. O'Brien, USA
COMMUNICATING BASIC SCIENCE TO THE CLINICIAN - BRIDGING THE GAP
C.A. Paterson, USA
THE ROLE OF META-ANALYSES IN EVALUATING DRUG EFFECTS:
THE COCHRANE APPROACH
R. Wormald, UK
THE DIFFICULTIES OF PUBLISHING NEGATIVE RESULTS AND ITS UNTOWARD EFFECT ON
SCIENTIFIC RESEARCH
B. Schwartz, USA
THE PROS AND CONS OF CONDUCTING MULTINATIONAL CLINICAL STUDIES
R. Vogel, USA
INVESTIGATIVE SITE NETWORKING IN OPHTHALMIC CLINICAL STUDIES
J. Tauber, USA
OPHTHALMIC CLINICAL STUDIES - IS IT WORTHWHILE TO PARTICIPATE (PATIENTS &
INVESTIGATORS POINTS OF VIEW)
R. David, USA
THE ORIGIN AND RAMIFICATION OF BLOOD VESSELS IN THE EYE - STRUCTURE ACTIVITY
RELATIONSHIP
D. Armstrong, USA
OCULAR EFFECTS OF GINGKO BILOBA EXTRACT: REALITY OR FANTASY?
F. Drago, Italy |
